Nitric oxide production and arachidonic acid metabolism in platelet membranes of coronary heart disease patients with and without diabetes

Medical Principles and Practice

Volumn 12, Issue 1, 2003, Pages 10-16

  Tretjakovsa, Peteris ^a,b   Kalnins, Uldis ^a   Dabina, Inese ^a   Erglis, Andrejs ^a   Dinne, Iveta ^a   Jurka, Antra ^a   Latkovskis, Gustavs ^a   Zvaigzne, Agnis ^a   Pirags, Valdis ^a  

^a UNIVERSITY OF LATVIA   (Latvia)

^b PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

Author keywords

Arachidonic acid; Coronary artery disease; Diabetes; Nitric oxide; Platelet

Indexed keywords

ARACHIDONIC ACID; NITRATE; NITRIC OXIDE; NITRITE; PHOSPHOLIPID;

ADULT; AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GENDER; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; PERIPHERAL VASCULAR DISEASE; SPECTROPHOTOMETRY; STATISTICAL SIGNIFICANCE; THROMBOCYTE MEMBRANE;

ADULT; AGED; ARACHIDONIC ACID; BLOOD PLATELETS; CELL MEMBRANE; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRATES; NITRITES; PHOSPHOLIPIDS; PLATELET ACTIVATION; SPECTROPHOTOMETRY;

EID: 12244286041     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068154     Document Type: Article

References (37)

1. Rao GH, Rao AT: Pharmacology of platelet activation-inhibitory drugs. Indian J Physiol Pharmacol 1994;38:69-84.
2. Willerson JT: Conversion from chronic to acute coronary heart disease syndromes: Role of platelets and platelet products. Tex Heart Inst J 1995;22:13-19.
3. Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP: L-Arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb 1994;14:1529-1533.
4. Anfossi G, Russo I, Massucco P, Mattiello L, Perna P, Tassone F, Trovati M: L-Arginine modulates aggregation and intracellular cyclic 3,5-guanosine monophosphate levels in human platelets: Direct effect and interplay with antioxidative thiol agent. Thromb Res 1999;94:307-316.
5. Wang GR, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME: Mechanism of platelet inhibition by nitric oxide: In vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci USA 1998;95:4888-4893.
6. Salvemini D: Regulation of cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci 1997;53:576-582.
7. Tsikas D, Ikic M, Tewes KS, Raida M, Frolich JC: Inhibition of platelet aggregation by S-nitrosocysteine via cGMP-independent mechanisms: Evidence of inhibition of thromboxane A2 synthesis in human blood platelets. FEBS Lett 1999;442:162-166.
8. Fujimoto Y, Tagano S, Ogawa K, Sakuma S, Fujita T: Comparison of the effects of nitric oxide and peroxynitrite on the 12-lipoxygenase and cyclooxygenase metabolism of arachidonic acid in rabbit platelets. Prostaglandins Leukot Essent Fatty Acids 1998;59:95-100.
9. Luscher TF, Pfisterer M: Thrombocyte inhibitors in cardiovascular therapy. Schweiz Rundsch Med Prax 1990;79:1132-1141.
10. Lyons D: Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease. Int J Cardiol 1997;62:S101-S109.
11. Tretjakovs P, Kalnins U, Dabina I, Dinne I, Erglis A, Kumsars I, Jurka A: Plasma HDL-cholesterol has an effect on nitric oxide production and arachidonic acid metabolism in the platelet membranes of coronary heart disease patients without LDL-hypercholesterolemia. Med Sci Monit 2000;6:507-511.
12. Zvaigzne A, Bumbure A, Tretjakovs P, Lejnieks A, Pirags V: Regulation of synthesis and activity of protein kinase C-β1 in platelets of diabetic patients after in vitro incubation; in Heilmeyer L, Friedrich P (eds): Protein Modules in Cellular Signalling. IOS Press, NATO Science Series A (Life Sciences), 2001, vol 318, pp 81-88.
13. Craven PA, Studer RK, DeRubertis FR: Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats: Evidence for protein kinase C-mediated suppression of the cholinergic response. J Clin Invest 1994;93:311-320.
14. Kajita K, Ishizuka T, Miura A, Kanoh Y, Ishizawa M, Kimura M, Yasuda K: Increased platelet aggregation in diabetic patients with microangiopathy despite good glycemic control. Platelets 2001;12:343-351.
15. 15N]nitrate in biological fluids. Anal Biochem 1982;126:131-138.
16. Marzinzig M, Nussler AK, Stadler J, Marzinzig E, Barthlen W, Nussler NC, Berger HG, Morris SM, Bruckner UB: Improved methods to measure end products of nitric oxide in biological fluids: Nitrite, nitrate, and S-nitrosothiols. Nitric Oxide 1997;1:177-189.
17. Moshage H: Nitric oxide determinations: Much ado about NO.-thing? Clin Chem 1997;43:553-556.
18. Navarro-Gonzalvez JA, Garcia-Benayas C, Arenas J: Semiautomated measurement of nitrate in biological fluids. Clin Chem 1998;44:679-681.
19. Neufeld EJ, Wilson DB, Sprecher H, Majerus PW: High affinity esterification of eicosanoid precursor fatty acids by platelets. J Clin Invest 1983;72:214-220.
20. Takahashi R, Morita I, Saito Y, Ito H, Murota S: Increased arachidonic acid incorporation into platelet phospholipids in type 2 (non-insulin-dependent) diabetes. Diabetologia 1984;26:134-137.
21. Niwa Y, Sakane T, Tangichi S: Phospholipid transmethylation in the membrane of human neutrophils and lymphocytes. Arch Biochem Biophys 1984;234:7-14.
22. Neufeld EJ, Marjerus PW: Arachidonate release and phosphotidic acid turnover in stimulated human platelets. J Biol Chem 1983;258:2461-2467.
23. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972;18:449-502.
24. Sievi E, Lahteenmaki TA, Alanko J, Vuorinen P, Vapaatalo H: Nitric oxide a regulator of prostacyclin synthesis in cultured rat heart endothelial cells. Arzneimittelforschung 1997;47:1093-1098.
25. Pigazzi A, Heydrick S, Folli F, Benoit S, Michelson A, Loscalzo J: Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. J Biol Chem 1999;274:14368-14375.
26. Murohara T, Scalia R, Lefer AM: Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells: Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. Circ Res 1996;78:780-789.
27. Riddell DR, Graham A, Owen JS: Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway: Implications for vascular disease. J Biol Chem 1997;272:89-95.
28. Anfossi G, Russo I, Massucco P, Mattiello L, Cavalot F, Tassone F, Perna P, Giori A, Trovati M: Platelet sensitivity to prostacyclin is reduced in obesity. Diabetologia 1998;41 (suppl 1):A328.
29. Anwaar I, Gottsater A, Wallmark A, Hedblad B, Lindgarde F, Mattiasson I: Intraplatelet cyclic 3′,5′ guanosine monophosphate is related to serum cholesterol. Int Angiol 1996;15:201-206.
30. McDonagh PF, Hokama JY: Microvascular perfusion and transport in the diabetic heart. Microcirculation 2000;7:163-181.
31. Abbate R, Pinto S, Panetta A, Favilla S, Prisco D, Paniccia R, Vanni D, Gensini GF, Neri Serneri GG: Platelet synthesis of cyclooxygenase and lipoxygenase products in type I and type II diabetes. Prostaglandins Leukot Essent Fatty Acids 1988;31:9-15.
32. Butkus A, Shirey EK, Schumacher OP: Thromboxane biosynthesis in platelets of diabetic and coronary artery diseased patients. Artery 1982;11:238-251.
33. Ruiz C, Alegria A, Barbera R, Farre R, Lagarda MJ: Lipid peroxidation and antioxidant enzyme activities in patients with type 1 diabetes mellitus. Scand J Clin Lab Invest 1999;59:99-105.
34. Mehta JL, Chen LY: Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. J Lab Clin Med 1996;127:287-295.
35. Eynard AR, Tremoli E, Caruso D, Magni F, Sirtori CR, Galli G: Platelet formation of 12-hydroxy-eicosatetraenoic acid and thromboxane B2 is increased in type IIA hypercholesterolaemic subjects. Atherosclerosis 1986;60:61-66.
36. Schmidt K, Klatt P, Graier WF, Kostner GM, Kukovetz WR: High-density lipoprotein antagonizes the inhibitory effects of oxidized low-density lipoprotein and lysolecithin on soluble guanylyl cyclase. Biochem Biophys Res Commun 1992;182:302-308.
37. Oster O, Prellwitz W: Selenium and cardiovascular disease. Biol Trace Elem Res 1990;24:91-103.